Company news
Vir Biotechnology, Inc. news in 2020
Vir Biotechnology, Inc.'s news releases, calls and decks from 2020, newest first.
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
December 16, 2020
Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors
December 9, 2020
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results
November 9, 2020
Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
November 5, 2020
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020
October 26, 2020
Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
October 20, 2020
Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference
October 12, 2020
Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection
October 8, 2020
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
October 5, 2020
Vir Biotechnology Appoints Janet Napolitano to its Board of Directors
August 31, 2020
Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
August 30, 2020
Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress™
August 19, 2020
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
August 10, 2020
Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors
July 9, 2020
Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
May 28, 2020
Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
May 26, 2020
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 11, 2020
Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
May 7, 2020
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020
April 27, 2020
VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
April 14, 2020
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
March 25, 2020
Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
March 24, 2020
Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19
March 11, 2020
Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses
March 10, 2020
Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19
February 24, 2020
Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2
February 11, 2020
Decks in 2020
- H.C. Wainwright 22nd Annual Global Investment Conference (September 2020)
Conference · 28 slides · Sep 16, 2020